Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: Where the Preclinical Rationale Holds
DOI:
https://doi.org/10.5281/zenodo.22649559Keywords:
Tumour Microenvironment Modulation to Overcome Checkpoint Resistance, Translational medicine; Evidence synthesis; Clinical implementation; Health services researchAbstract
Tumour Microenvironment Modulation to Overcome Checkpoint Resistance is an area of active development in translational
medicine, with evidence that has accumulated unevenly across its component questions. We review the current evidence base for
tumour microenvironment modulation to overcome checkpoint resistance, spanning analytical, clinical, implementation,
governance, and economic dimensions, focusing on where practice has converged and where it continues to vary, and set out the
practical considerations relevant to a service considering its adoption. We conclude that selective, context-specific use is best
supported by the evidence currently available, rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.7759/cureus.46454
Brankovic K, Kowalczyk B, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1016/j.ssci.2025.107028
Castellani R, Ristic C, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.2196/48633
Dumitrescu A, Andric D, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.1371/journal.pone.0305949
Eriksdottir B, Brankovic E, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1371/journal.pdig.0000514
Farkas I, Ionescu F, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.17219/acem/208596
Grabowski P, Petrescu G, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.7759/cureus.104086
Hendriksen W, Wojcik H, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1038/s41746-023-00852-5
Ionescu F, Foscarini I, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI:
1016/j.mayocpiqo.2022.09.004 10. Jankowiak G, Grabowski J, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1177/08404704241291226
Kowalczyk N, Novotna K, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1093/medlaw/fwad013
Lindqvist U, Urbanek L, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.2196/89834
Marchetti D, Doncheva M, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1007/s10916-024-02104-9
Novotna E, Eriksdottir N, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.3389/fdgth.2026.1896184
Ostrowski L, Lindqvist O, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.3390/diagnostics15162117
Petrescu S, Szabo P, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.4103/jrpp.jrpp_20_65
Quintero B, Balogh Q, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.3389/fdgth.2026.1763884
Ristic C, Castellani R, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.2196/48297
Szabo J, Jankowiak S, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1007/s00330-025-12031-z
Tarasov Q, Quintero T, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3389/fdgth.2026.1699005
Urbanek Z, Zielinski U, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3389/fdgth.2026.1834800
Vasquez A, Alvez V, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.2196/69678
Wojcik H, Hendriksen W, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.7759/cureus.46454
Zielinski O, Ostrowski Z, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1016/j.ssci.2025.107028
Andric V, Vasquez A, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.2196/48633
Balogh E, Emmerich B, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.1371/journal.pone.0305949
Chiriac F, Farkas C, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1371/journal.pdig.0000514
Doncheva M, Marchetti D, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a validation study". Trials 22(2017): 377-383. DOI: 10.17219/acem/208596
Emmerich T, Tarasov E, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.7759/cureus.104086
Foscarini C, Chiriac F, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1038/s41746-023-00852-5
Alvez D, Dumitrescu A, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1016/j.mayocpiqo.2022.09.004
Brankovic K, Kowalczyk B, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1177/08404704241291226
Castellani R, Ristic C, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1093/medlaw/fwad013
Dumitrescu A, Andric D, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.2196/89834
Eriksdottir B, Brankovic E, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1007/s10916-024-02104-9
Farkas I, Ionescu F, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.3389/fdgth.2026.1896184
Grabowski P, Petrescu G, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.3390/diagnostics15162117
Hendriksen W, Wojcik H, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.4103/jrpp.jrpp_20_65
Ionescu F, Foscarini I, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a scoping review". JAMA 44(2020): 498-506. DOI: 10.3389/fdgth.2026.1763884
Jankowiak G, Grabowski J, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.2196/48297
Kowalczyk N, Novotna K, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1007/s00330-025-12031-z
Lindqvist U, Urbanek L, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3389/fdgth.2026.1699005
Marchetti D, Doncheva M, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3389/fdgth.2026.1834800
Novotna E, Eriksdottir N, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.2196/69678
Ostrowski L, Lindqvist O, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.7759/cureus.46454
Petrescu S, Szabo P, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1016/j.ssci.2025.107028
Quintero B, Balogh Q, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.2196/48633
Ristic C, Castellani R, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.1371/journal.pone.0305949
Szabo J, Jankowiak S, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1371/journal.pdig.0000514
Tarasov Q, Quintero T, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.17219/acem/208596
Urbanek Z, Zielinski U, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.7759/cureus.104086
Vasquez A, Alvez V, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1038/s41746-023-00852-5
Wojcik H, Hendriksen W, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1016/j.mayocpiqo.2022.09.004
Zielinski O, Ostrowski Z, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1177/08404704241291226
Andric V, Vasquez A, et al. "Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1093/medlaw/fwad013
